Formycon: „Wir gehören zur Spitzengruppe“ - Interview www.4investors.de/nachrichten/...
Formycon: „Wir gehören zur Spitzengruppe“ - Interview www.4investors.de/nachrichten/...
🚀 Free alerts → https://gunpowderalerts.in/go?utm_source=bluesky&utm_medium=social&utm_campaign=high_priority_filing
#IndiaMarkets #Healthcare #MarketNotice
🚀 Free alerts → https://gunpowderalerts.in/go?utm_source=bluesky&utm_medium=social&utm_campaign=high_priority_filing
#IndiaMarkets #Healthcare #MarketNotice
Zydus Lifesciences and Formycon AG jointly announced that the USFDA has accepted for review the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), which the companies believe is the first publicly...
🧵 continued ↓
Zydus Lifesciences and Formycon AG jointly announced that the USFDA has accepted for review the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), which the companies believe is the first publicly...
🧵 continued ↓